home
顺序
主题
题目
日子
126
HLB's US subsidiary promotes efficacy of liver cancer drug Rivoceranib
admin
2023.03.27
125
PSMC emerges as core of HLB Group interested in CAR-T drugs
admin
2023.03.07
124
HLB's anticancer drug receives greenlight in China
admin
2023.02.02
123
HLB set to apply for conditional domestic approval of rivoceranib
admin
2022.11.09
122
HLB completes preparatory meeting with FDA for approval of liver cancer drug
admin
2022.10.14
121
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option
admin
2022.10.13
120
Clinical Trial Results Allude to New Options for Patients With HCC
admin
2022.10.07
119
Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC
admin
2022.10.07
118
Novel CAR-T therapies from HLB and GC Cell’s US affiliates take spotlight
admin
2022.09.27
117
HLB drug candidate shows longest liver cancer survival duration
admin
2022.09.14